Biomarkers in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00817336
Recruitment Status : Completed
First Posted : January 6, 2009
Results First Posted : August 2, 2017
Last Update Posted : August 2, 2017
Information provided by (Responsible Party):
Nathan Kline Institute for Psychiatric Research

January 5, 2009
January 6, 2009
December 15, 2016
August 2, 2017
August 2, 2017
June 2009
July 2011   (Final data collection date for primary outcome measure)
  • PANSS Total [ Time Frame: 6 weeks ]
    Positive and Negative Symptom Scale (PANSS) range 30-210
  • MMN Amplitude [ Time Frame: 6 weeks ]
    Final MMN amplitude
Change in biomarkers (QEEG, Auditory P50/mismatch negativity (MMN)/N1, Auditory P300, Visual P1) [ Time Frame: 6 weeks ]
Complete list of historical versions of study NCT00817336 on Archive Site
  • MATRICS [ Time Frame: 6 weeks ]
    MATRICS assessing 7 domains (Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition. Raw scores are converted into a composite T-score (normative mean = 50; standard deviation = 10), where higher values indicated less impairment.
  • Visual P1 [ Time Frame: 6 weeks ]
  • MATRICS [ Time Frame: 6 weeks ]
  • PANSS [ Time Frame: 6 weeks ]
  • CGI [ Time Frame: 6 weeks ]
  • Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: 6 weeks ]
  • Finger Tapping Motor Sequence Task (MST) [ Time Frame: 6 weeks ]
Not Provided
Not Provided
Biomarkers in Schizophrenia
Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia
N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia. Further, several novel glutamate-based classes of compound are presently in development as potential novel treatments for persistent negative and cognitive symptoms. The study will assess effectiveness of a NMDA-based intervention on biomarkers related to schizophrenia as a mechanism for developing appropriate outcome batteries for future trials of novel compounds.
16 in- or outpatients with DSM-IV-TR schizophrenia or schizoaffective disorder and prominent negative symptoms will be recruited for this study. This study will consist of a randomized trial of D-serine (60 mg/kg/d) vs. placebo using a crossover design with a 2-week baseline lead-in, and two 6-week intervention arms separated by a two week, placebo controlled washout period. Biomarkers will be assessed at baseline for each treatment arm, acutely (day 7) following treatment initiation, and following 6 weeks of treatment (6 biomarker sessions total). Primary biomarker outcome measures will include 1) amplitude of the mismatch negativity (MMN) waveform and 2) amplitude of the visual P1 potential. Symptomatic outcome measures will include PANSS and composite score of the MATRICS neuropsychological battery. The study will be supported from ongoing NIMH-funded Cooperative Drug Development Grant (CDDG) to the PI.
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Schizophrenia
  • Schizoaffective Disorder
  • Drug: D Serine
    60 mg/kg/day
  • Drug: Placebo
  • Experimental: D-serine
    60 mg/kg/day
    Intervention: Drug: D Serine
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Age 18-64
  • SCID diagnosis of Schizophrenia or Schizoaffective Disorder.
  • PANSS 3 factor negative symptom (screening and baseline visit 1 and visit 3) score of >20 and PANSS total score between 60-110. Any degree of positive symptoms is acceptable but the total PANSS score must not exceed 110.
  • SAS total score less than or equal to 12 and a Calgary Depression Inventory total score less than or equal to 10 and suicide (item 8) less than moderate (<2).
  • Two consecutive CGI ratings at screening and baseline (visit 1 and 3) with no change in score.
  • Estimated Glomerular Filtration Rate (GFR)(a measure of renal function) greater than or equal to 60.

Exclusion criteria:

  • Organic brain disorder, including epilepsy; mental retardation; or a medical condition whose pathology or treatment would likely alter the presentation or treatment of schizophrenia or significantly increase the risk associated with any of the proposed treatments
  • Current DSM-IV diagnosis of drug/alcohol abuse in last month and current DSM-IV diagnosis of drug/alcohol dependence in last 6 months
  • Pregnant female patients
  • Impaired renal function
  • Significant extrapyramidal symptoms (as reflected by a total score of 10 or above on the SAS scale), and depressive symptoms (as reflected by a score of 10 or above on the Calgary Depression Scale for Schizophrenia)
  • Patients who are unable to or unwilling to participate in the Cognitive assessment (MATRICS) and the electrophysiology tasks .
  • Patients on clozapine
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Nathan Kline Institute for Psychiatric Research
Nathan Kline Institute for Psychiatric Research
Not Provided
Principal Investigator: Daniel C Javitt, MD, PhD New York University
Nathan Kline Institute for Psychiatric Research
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP